Johnson & Johnson Market Cap 2010-2025 | JNJ

Johnson & Johnson market cap history and chart from 2010 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Johnson & Johnson market cap as of July 08, 2025 is $373.59B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $373.591B $88.821B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $732.476B 56.17
AbbVie (ABBV) United States $331.430B 18.27
Novo Nordisk (NVO) Denmark $309.514B 20.51
Novartis AG (NVS) Switzerland $257.969B 14.73
Roche Holding AG (RHHBY) Switzerland $257.158B 0.00
Merck (MRK) United States $203.142B 10.39
Pfizer (PFE) United States $143.499B 7.86
Sanofi (SNY) France $118.503B 11.67
Bayer (BAYRY) Germany $30.023B 6.11
Innoviva (INVA) United States $1.187B 12.44